Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Two faces of ET: CALR and JAK2 BLOOD Chao, M. P., Gotlib, J. 2014; 123 (10): 1438–40

Abstract

In this issue of Blood, Rumi et al and Rotunno et al demonstrate that essential thrombocythemia (ET) patients with calreticulin mutations exhibit lower leukocyte and hemoglobin values, higher platelet counts, and a lower thrombosis risk vs JAK2-mutated ET. Calreticulin-mutated ET appears to be a distinct entity with a more indolent course.

View details for DOI 10.1182/blood-2014-01-547596

View details for Web of Science ID 000335844600005

View details for PubMedID 24627549